How many drugs treat Pneumonia?

Drug Landscape tracks 10 marketed treatments for Pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cefradex	cefradine	Bristol-Myers Squibb	cefradine	Matrix metalloproteinase-9	1974-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Cephalotin	cefalotin	Eli Lilly	cefalotin	Solute carrier family 22 member 8	1974-01-01
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Minocyclin	Minocyclin	University of Southern California		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B
Meclan	MECLOCYCLINE	Johnson And Johnson	meclocycline
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Cephradin	Cephradin	Sohag University		Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 10 drugs in Pneumonia
Bristol-Myers Squibb · 2 drugs in Pneumonia
Astellas Pharma · 1 drug in Pneumonia
Eli Lilly · 1 drug in Pneumonia
Johnson And Johnson · 1 drug in Pneumonia
Pfizer · 1 drug in Pneumonia
Pfizer Inc. · 1 drug in Pneumonia
Rempex · 1 drug in Pneumonia
Sohag University · 1 drug in Pneumonia
University of Southern California · 1 drug in Pneumonia
Assistance Publique - Hôpitaux de Paris · 1 drug in Pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia:

Cite this brief

Drug Landscape (2026). Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia. Accessed 2026-06-10.

Pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing